TY - JOUR
T1 - Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer
AU - Yamauchi, Takeyoshi
AU - Watanabe, Masahiko
AU - Kubota, Tetsuro
AU - Hasegawa, Hirotoshi
AU - Ishii, Yoshiyuki
AU - Endo, Takashi
AU - Kabeshima, Yasuo
AU - Yorozuya, Kyoko
AU - Yamamoto, Kentaro
AU - Mukai, Makio
AU - Kitajima, Masaki
N1 - Funding Information:
Supported by a grant from the Ministry of Health and Welfare. Presented at the American Association of Cancer Research Meeting, San Francisco, California, April 1 to 5, 2000. Address reprint requests to Dr. Watanabe: Department of Surgery, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2002
Y1 - 2002
N2 - PURPOSE: Epidemiologic studies indicate that the use of nonsteroidal anti-inflammatory drugs, which inhibit cyclooxygenase activity, reduce the risk of colorectal cancer. In addition, several studies demonstrate increased expression of cyclooxygenase-2 in human colorectal cancer tissues. However, the role of cyclooxygenase-2 expression in colorectal cancer has not yet been fully established. The aim of this study was to clarify the clinicopathologic significance of cyclooxygenase-2 expression in human colorectal cancer. METHODS: A total of 232 surgically resected colorectal cancer specimens were analyzed immunohistochemically with the use of a murine anti-human cyclooxygenase-2 monoclonal antibody. Cyclooxygenase-2 expression was then compared with clinicopathologic background and survival outcome. RESULTS: Cyclooxygenase-2 was expressed in the cytoplasm of the cancer cells but not in normal epithelium. Cyclooxygenase-2 expression was noted in 71.6 percent (166/232) of the cancer patients and correlated significantly with histologic type (P = 0.033), depth of invasion (P = 0.016), pathologic stage (P = 0.020), and metachronous liver metastasis (P = 0.001). Multivariate analysis for factors associated with metachronous liver metastasis showed that cyclooxygenase-2 expression was one of the independent risk factors, second only to lymph node metastasis. Patients with cyclooxygenase-2 expression showed a significantly poorer outcome compared with those without cyclooxygenase-2 expression (P = 0.002). CONCLUSION: Cyclooxygenase-2 expression in the primary lesion may be a useful marker for evaluating prognosis and liver metastasis in patients with colorectal cancer.
AB - PURPOSE: Epidemiologic studies indicate that the use of nonsteroidal anti-inflammatory drugs, which inhibit cyclooxygenase activity, reduce the risk of colorectal cancer. In addition, several studies demonstrate increased expression of cyclooxygenase-2 in human colorectal cancer tissues. However, the role of cyclooxygenase-2 expression in colorectal cancer has not yet been fully established. The aim of this study was to clarify the clinicopathologic significance of cyclooxygenase-2 expression in human colorectal cancer. METHODS: A total of 232 surgically resected colorectal cancer specimens were analyzed immunohistochemically with the use of a murine anti-human cyclooxygenase-2 monoclonal antibody. Cyclooxygenase-2 expression was then compared with clinicopathologic background and survival outcome. RESULTS: Cyclooxygenase-2 was expressed in the cytoplasm of the cancer cells but not in normal epithelium. Cyclooxygenase-2 expression was noted in 71.6 percent (166/232) of the cancer patients and correlated significantly with histologic type (P = 0.033), depth of invasion (P = 0.016), pathologic stage (P = 0.020), and metachronous liver metastasis (P = 0.001). Multivariate analysis for factors associated with metachronous liver metastasis showed that cyclooxygenase-2 expression was one of the independent risk factors, second only to lymph node metastasis. Patients with cyclooxygenase-2 expression showed a significantly poorer outcome compared with those without cyclooxygenase-2 expression (P = 0.002). CONCLUSION: Cyclooxygenase-2 expression in the primary lesion may be a useful marker for evaluating prognosis and liver metastasis in patients with colorectal cancer.
KW - Colorectal cancer
KW - Cyclooxygenase-2 (COX-2)
KW - Immunohistochemistry
KW - Liver metastasis
UR - http://www.scopus.com/inward/record.url?scp=18244401954&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=18244401954&partnerID=8YFLogxK
U2 - 10.1007/s10350-004-6120-5
DO - 10.1007/s10350-004-6120-5
M3 - Article
C2 - 11786771
AN - SCOPUS:18244401954
SN - 0012-3706
VL - 45
SP - 98
EP - 103
JO - Diseases of the colon and rectum
JF - Diseases of the colon and rectum
IS - 1
ER -
